Trials / Completed
CompletedNCT01090622
Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)
Phase 2a, Double-blind, Placebo-controlled, 2-period, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients With Inherited Erythromelalgia.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Xenon Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether XPF-001 is safe and effective in the treatment of pain caused by Inherited Erythromelalgia (IEM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XPF-001 | Oral capsule |
| DRUG | Placebo | Oral capsule |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2010-08-01
- Completion
- 2010-09-01
- First posted
- 2010-03-22
- Last updated
- 2012-03-16
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01090622. Inclusion in this directory is not an endorsement.